| COUNTRY |
FUNDING BODY |
TYPE OF STUDIES |
AMOUNT AVAILABLE |
DEADLINE |
Belgium |
KCE |
Clinical trials on COVID-19 |
NA |
15-04-2021 |
Czech Republic |
Czech Technology Agency |
Innovative solutions for combating the current epidemic and improving preparedness in future outbreaks |
40 M CZK per project |
31-12-2020 |
Germany |
Federal Ministry of Education and Research |
Vaccine development and clinical trials |
NA |
31-12-2020 |
Germany |
Volkswagen Foundation |
Basic research and first phases of clinical research for new drugs against COVID-19 and emerging viral diseases |
700K €/project |
10-12-2020 |
Malta |
Malta Council for Science and Technology & Malta Enterprise |
Epidemiology, Basic Science, Clinical Research, Social Sciences, IT, |
5,3 M € total |
30-12-2020 |
Scotland |
NHS Scotland |
Innovative solutions that can support the NHS Scotland in its fight against COVID-19 |
£25K |
Rolling applications |
Spain |
Banco Santander/Crue Universidades Espanolas |
Big data analysis, clinical research, basic science, socio-economic impact, innovative products and solutions for crisis mitigation |
8,5 M € Total |
Rolling applications until 18 December 2020 |
Sweden |
Swedish Research Council |
Exceptional redirection of ongoing grants to focus on COVID19 |
No more than 1/3 of amount yearly allocate |
Ongoing – requires an authorization |
United Kingdom |
British Heart Foundation |
Clinical research on cardiovascular disease and COVID19 |
Not specified – applications must align with UK COVID19 priorisation process |
Rolling applications evaluated weekly |
United Kingdom |
Foundation for a smoke-free world |
Preclinical, clinical and epidemiological research at the intersection of smoking and COVID-19 |
US$ 500K |
15 -12- 020 |
United Kingdom |
UK MRC |
Virology, Immunity and Pathophysiology, Diagnostics, Epidemiology, PPE and other protective material, Public Health, Clinical Research, Vaccines, Health Care and Delivery |
Variable depending on project needs |
Rolling call - 1 Apr 2021 |
United Kingdom |
NIHR |
Which drug or antibody interventions are effective, cost-effective, safe and most acceptable for prophylaxis of COVID-19 in a UK care home setting? |
NA |
11-11-2020 |
United Kingdom |
NIHR |
Urgent Public Health Research – through National Priorisation Process |
NA |
Rolling applications |
United Kingdom |
UK Research and Innovation |
Innovative solutions to gather critical data, support manufacture or wide scale adoption of an intervention, better understand and mitigate impact of the epidemic |
80% of the full economic cost |
none - apply at any time |
Pan European |
Partnership for Advanced Computing in Europe (PRACE) |
Projects requesting computer resources for: epidemiology, bioinformatics, bio-simulation, biomolecular analysis, other studies to mitigate the epidemic |
Resources requested reviewed for each proposal |
Open until further notice |
|
